Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Marasprint,
Insider buying is always welcomed by shareholders, I completely agree. That said, I believe management remains inside a black out period due to Q1 ending near term. Unfortunately most companies officers are precluded from buying at this time of year due to the fact that their K's are filed so close to Q1 end.
No members of any public company's management may trade in their stock from the period of a quarter end, to the time they publicly file their financials with the SEC making them public information.
porscha,
By any chance does the Ferrari license plate have ROBIN-1 on it? ;)
Croxall...
Revenue in 2014 generated without the benefit of major catalysts, such as Markman hearings and trials. In 2014, Marathon’s subs had only two Markman hearings no US trials and 2 infringement trials in Germany. However, in 2015, we have already had 3 Markman hearings covering 31 defendants. Subsidiaries have an additional 7 Markman hearings covering 25 defendants, along with 3 US trials covering 6 defendants and 6 German trials covering 12 defendants. Believe current Markman / trial schedule for 2015 has potential to be a significant revenue catalyst for company.
In 2014 Marathon through its wholly-owned operating subsidiaries acquired nine portfolios totaling 260 patents and patent rights.
As others have stated repeatedly, it's annual revenue growth that is the proper measure for assessing growth of companies in this space. Trying to evaluate players in this space based on quarterly growth is inherently problematic in my opinion.
"Since the beginning of the 2015, we have already had three Markman hearings covering 31 defendants. Throughout the remainder of 2015, our subsidiaries have an additional seven Markman hearings covering 25 defendants, along with nine trials covering 18 defendants. We believe the current Markman and trial schedule for 2015 has the potential to trigger significant revenue events," Mr. Croxall concluded.
Acquisition of Patents
In 2014 Marathon through its wholly-owned operating subsidiaries acquired the following portfolios:
> Dynamic Advances, LLC (4 patents)
> IP Liquidity Ventures, LLC (6 Patents)
> Sarif Biomedical, LLC (5 Patents)
> Selene Communication Technologies, LLC (3 Patents)
> Clouding Corp. (70 Patents)
> TLI Communications (6 Patents)
> MedTech GmbH (4 Patents)
> OrthoPhoenix (158 Patents)
> TLIF (4 Patents)
526% Increase in year over year revenue growth and $4.2 million in Non-GAAP income up from a $300k loss the previous year. You won't find many companies that can claim the same.
> 2014 revenues of $21.4 million, up 526% from $3.4 million from the prior year.
> Achieved 2014 Non-GAAP net income of $4.2 million, or $0.36 per common share, compared to a 2013 net loss of $(300,000), or $(0.03) per share.
> Cash and cash equivalents of $5.1 million as of December 31, 2014, compared to $3.6 million as of December 31, 2013.
> Acquired nine patent portfolios in active enforcement consisting of 260 patents during the year bringing total to 378.
> Currently have 19 portfolios covering 14 distinct technology areas, 16 in active licensing campaigns compared to four at year-end 2013.
> Twelve portfolios have generated revenue to date, up from three portfolios through the end of 2013.
> Six portfolios have generated a net positive return in excess of their cost to acquire and enforce the portfolio.
> Added seasoned IPNav veterans Rick Sanchez and Umesh Jani to the Marathon team.
> Launched Opus Analytics patent analysis platform.
Commenting on the Company's 2014 financial results, Doug Croxall, Founder & Chief Executive Officer of Marathon, stated, "Marathon saw significant revenue growth in 2014. Revenues of $21.4 million were up 526% year-over-year. This increase in our top-line can be attributed to strong execution of our patent licensing campaigns and an increase in the number of patents and patent portfolios acquired during 2014."
"Since the beginning of the 2015, we have already had three Markman hearings covering 31 defendants. Throughout the remainder of 2015, our subsidiaries have an additional seven Markman hearings covering 25 defendants, along with nine trials covering 18 defendants. We believe the current Markman and trial schedule for 2015 has the potential to trigger significant revenue events." Mr. Croxall concluded.
If recent hearings are any indication, we might be getting to the point where the pendulum is starting to swing back.
While I think the CAFC is still a concern, I wonder if their power may have peaked. What was once a crap shoot with them, like a bet on black or red, seems to possibly be subtly changing, assuming Google isn't the defendant. ;)
If you review the Teva v. Sandoz case, more deference appears to be being given to trial court.
On January 20, 2015, the Supreme Court issued its decision in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., finding that the Federal Rules of Civil Procedure call for some deference in the claim construction standard of review. In particular, the Court held that when claim construction is based on external evidence, a district court’s findings of subsidiary facts are to be reviewed for clear error, while its ultimate claim construction is to be reviewed de novo. Although this decision changes the Federal Circuit’s nearly 20-year practice of applying full de novo review since the Supreme Court’s 1996 decision in Markman v. Westview Instruments, Inc., it is not surprising in view of the Court’s recent decisions that refuse to make exceptions to the usual rule for patent matters.
http://www.pharmapatentsblog.com/2015/01/22/supreme-court-calls-for-some-deference-in-claim-construction-standard-of-review/
Great read, thanks for posting it. Based on my interpretation, the tide seems to be subtly changing, just as some of us envisioned it may.
I would also echo what Patentminer said. It's important to note that the market generally fears potential reform because it represents the unknown. To me however, the fear appears to relate more to the perception of it, versus the reality of it.
I wholeheartedly agree with PM's comments in that if some of the reform was passed as is, it has the potential of both driving down asset costs, as well as possibly driving strong assets right into the hands of companies like Marathon. This would seem to have the potential of being a literal boom for the top NPE's like Marathon as they will likely see pronounced margin expansion.
The irony in my opinion is that even the most stringent of current proposed reform appears to have the potential of actually helping the top NPE's, not harming them. Small inventors and companies with patents will likely flock to companies like Marathon in droves to partner on their enforcement efforts because they will no longer be able to prosecute it on their own. The risk and cost to smaller companies and investors would simply be too high driving them right to a top NPE. The demand for a top NPE could possibly explode while the supply remains very finite.
In my mind, the irony in all the reform discourse, while it has caused investor uncertainty, is that I believe its ultimate effect could materially benefit the growth and profitability of a select group of top NPE's.
One last thing, people have recently commented about how the sector is out of favor. I think that completely accurate and self evident. That said, in my personal experience over the years, the best time to make longer term investments is often at that point where a sector is out of favor. Generally speaking, when there is a rotation back into a particular sector, it's typically the leaders (Acacia and Marathon) who have the highest likelihood of generating the largest percentage gains in the shortest order.
Again, based on the article you posted Hispeed, one must wonder if that tide is already beginning to shift.
Nice 10k trade at $5.05.
What's your email? I will ask someone to forward to you.
Not sure if Chardan's is coverage on Marathon or whether it is a research note that features Marathon. Nice to see the attention regardless. I am personally a big fan of Mike Latimore at Northland. Guy has earned my respect and many others by his past work over many years.
Mike Latimore is the analyst. Well regarded analyst and an excellent report. Hands down the best to date imo. Really nice to see such an aggressive target in an initiation report.
SilverSun Technologies Completes Acquisition of Accounting Technology Resources
California Firm's 2014 Revenue Exceeded $1.5 Million
LIVINGSTON, NJ--(Marketwired - Mar 12, 2015) - SilverSun Technologies, Inc. (OTCQB: SSNT) (OTCBB: SSNT) announced today that its wholly owned subsidiary, SWK Technologies, Inc., a national provider of transformational business technology solutions and services, closed on the acquisition of Accounting Technology Resources ("ATR"), a leading California-based reseller of Sage Software and Acumatica applications. ATR has implemented technology solutions at prominent companies throughout California.
The deal will add more than $1,500,000 in annual revenue and will be immediately accretive to SilverSun's earnings. The acquisition cost $255,000 in the form of a $175,000 3-year note and $80,000 cash.
Mark Meller, CEO of SilverSun, stated, "This transaction further solidifies our position as one of the largest resellers of Sage Software in the United States. We continue to execute on our business plan to increase value for our shareholders by increasing profitable sales and acquiring companies and technologies. We are exploring several additional acquisitions, and hope to be in a position to announce several new transactions in the coming weeks and months."
"We are very excited to have ATR and its founder, Karen Espinoza McGarrigle, join our team," added Jeffrey D. Roth, CEO of SWK Technologies. "This acquisition makes SWK Technologies a dynamic force with significant market presence in the western part of the U.S. With our management talent, in-house expertise, and financial resources, we are confident that the combined companies will be able to accelerate sales and earnings growth. We are very excited about our future prospects."
About SilverSun Technologies, Inc.
SilverSun Technologies is involved in the acquisition and build-out of technology and software companies. The Company's growth strategy is to acquire firms in the extensive and expanding, but highly fragmented, business solutions marketplace, as it seeks to create substantial value for shareholders. Since June 2004, SilverSun has acquired SWK Technologies, Inc., Business Tech Solutions Group, Inc., Wolen Katz Associates, AMP-BEST Consulting, Inc., Hightower, Inc., and ESC Software, Inc. Through its subsidiaries, the Company offers an array of accounting and business management products, including its own proprietary software, as well as a wide range of managed services and cloud services.
For additional information, visit SilverSun's corporate website: www.silversuntech.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to SilverSun Technologies, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Contact Information
Contact
SilverSun Technologies
Mark Meller
CEO
(973) 758-6108
Email Contact
SilverSun Technologies Completes Acquisition of Accounting Technology Resources
California Firm's 2014 Revenue Exceeded $1.5 Million
LIVINGSTON, NJ--(Marketwired - Mar 12, 2015) - SilverSun Technologies, Inc. (OTCQB: SSNT) (OTCBB: SSNT) announced today that its wholly owned subsidiary, SWK Technologies, Inc., a national provider of transformational business technology solutions and services, closed on the acquisition of Accounting Technology Resources ("ATR"), a leading California-based reseller of Sage Software and Acumatica applications. ATR has implemented technology solutions at prominent companies throughout California.
The deal will add more than $1,500,000 in annual revenue and will be immediately accretive to SilverSun's earnings. The acquisition cost $255,000 in the form of a $175,000 3-year note and $80,000 cash.
Mark Meller, CEO of SilverSun, stated, "This transaction further solidifies our position as one of the largest resellers of Sage Software in the United States. We continue to execute on our business plan to increase value for our shareholders by increasing profitable sales and acquiring companies and technologies. We are exploring several additional acquisitions, and hope to be in a position to announce several new transactions in the coming weeks and months."
"We are very excited to have ATR and its founder, Karen Espinoza McGarrigle, join our team," added Jeffrey D. Roth, CEO of SWK Technologies. "This acquisition makes SWK Technologies a dynamic force with significant market presence in the western part of the U.S. With our management talent, in-house expertise, and financial resources, we are confident that the combined companies will be able to accelerate sales and earnings growth. We are very excited about our future prospects."
About SilverSun Technologies, Inc.
SilverSun Technologies is involved in the acquisition and build-out of technology and software companies. The Company's growth strategy is to acquire firms in the extensive and expanding, but highly fragmented, business solutions marketplace, as it seeks to create substantial value for shareholders. Since June 2004, SilverSun has acquired SWK Technologies, Inc., Business Tech Solutions Group, Inc., Wolen Katz Associates, AMP-BEST Consulting, Inc., Hightower, Inc., and ESC Software, Inc. Through its subsidiaries, the Company offers an array of accounting and business management products, including its own proprietary software, as well as a wide range of managed services and cloud services.
For additional information, visit SilverSun's corporate website: www.silversuntech.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to SilverSun Technologies, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Contact Information
Contact
SilverSun Technologies
Mark Meller
CEO
(973) 758-6108
Email Contact
Good overview hispeed. Thank you for composing it.
Nice to see tangible evidence of them doing exactly what they publicly stated they intended to do.
SilverSun Technologies Closes Public Offering
LIVINGSTON, NJ--(Marketwired - Mar 10, 2015) - SilverSun Technologies, Inc. (the "Company" or "SilverSun") (OTCBB: SSNT) (OTCQB: SSNT) announced today that it has closed a public offering of its common stock and warrants to purchase common stock. There will be additional closings of this public offering. The Company offered 285,001 shares of its common stock at $4.24 per share and 142,501 warrants to purchase shares of its common stock at $0.01 per warrant to the public. SilverSun received gross proceeds from this first closing of the public offering, before deducting placement agency commissions and estimated offering expenses payable by SilverSun, of approximately $1,208,000.
Alexander Capital LP, the Company's Placement Agent, is acting as the sole book-running manager of the Offering and The Benchmark Company is acting as sub-agent.
The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital, sales and marketing activities, product development, general and administrative matters and capital expenditures.
The offering is being made pursuant to a registration statement on Form S-1 that SilverSun has filed with the Securities and Exchange Commission ("SEC") and which is effective. A final prospectus supplement containing important information relating to these securities was filed with the SEC. Copies of the final prospectus relating to these securities may be obtained by contacting Alexander Capital, L.P., 17 State Street, 5th Floor, New York, NY, 10004, telephone: (212) 687-5649 or email: info@alexandercapital.com. Electronic copies of the prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Alexander Capital, 17 State Street, New York, NY 10004, (855) 288-2539.
About SilverSun Technologies, Inc.
SilverSun Technologies is involved in the acquisition and build-out of technology and software companies. The Company's growth strategy is to acquire firms in the extensive and expanding, but highly fragmented, business solutions marketplace, as it seeks to create substantial value for shareholders. Since June 2004, SilverSun has acquired SWK Technologies, Inc., Business Tech Solutions Group, Inc., Wolen Katz Associates, AMP-BEST Consulting, Inc., Hightower, Inc., and ESC Software, Inc. Through its subsidiaries, the Company offers an array of ERP, EDI, WMS, BI and business management products, including its own proprietary software, as well as a wide range of value-added services.
For additional information, visit SilverSun's corporate website: www.silversuntech.com
Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to SilverSun Technologies, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Contact:
Contact
SilverSun Technologies
Mark Meller
CEO
(973) 758-6108
Email Contact
Medovex Corp. Enters Into Merger Agreement to Acquire Streamline, Inc.
ATLANTA, GA--(Marketwired - Mar 10, 2015) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, announced today that it has entered into a definitive merger agreement to acquire 100% of the stock of Streamline, Inc., a Minneapolis, Minnesota based medical technology company. Closing of the merger is subject to customary conditions and approval by Streamline shareholders at a meeting scheduled for March 25, 2015.
Medovex expects to combine Streamline's expertise in patient safety oriented durable medical equipment with Medovex's vision for acquiring and developing medical technology that solves significant challenges faced by health care providers. Streamline developed the IV Suspension System (ISS™), a patient equipment management device that makes the management of patients and their equipment easier, safer and more efficient within hospitals by combining the advantages of both stand-alone and bed-mounted IV pole in one system.
A demonstration of the Streamline ISS may be viewed here: Streamline
Jarrett Gorlin, CEO of Medovex, stated, "Pending approval, Streamline will be our first merger. According to Critical Care Medicine, there are roughly 100,000 critical care beds in U.S. hospitals. It is a turnkey acquisition and its product can immediately be brought to market in scale. The technology is patent protected, FDA cleared, already manufactured and extensively tested. We anticipate forming a U.S. marketing partnership in upcoming weeks followed by a full scale product launch."
Gorlin continued, "Streamline's ISS technology serves a growing need for safety and efficiency for both patients and caregivers in the hospital setting. The product provides caregivers with a more efficient means of handling the growing amount of patient equipment that remains with patients as they move about a hospital."
Current methods of intra-hospital transportation require cumbersome handling and control of patient beds and mobile IV stands during the transport process. It's during these transports that patient care can be compromised. The ISS also provides safety benefits to patients through reduction in IV line pull incidents.
A study from the Society for Academic Emergency Medicine revealed that adverse events occurred in 68% of the 340 transports observed. 49% of those events were related to the equipment, and more specifically 26% were related to equipment IV lines.
About Medovex:
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. Medovex's first pipeline product, the DenerveX™ device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement:
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Medovex believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including the risks that the Streamline ISS product may not prove to be efficient, that the Company will not be able to form a satisfactory U.S. marketing relationship, and that the Company's product may not prove effective in increasing the safety of intra-hospital patient transport, as well as the risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including but not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact Information
CONTACT INFORMATION
Medovex Corp.
Jason Assad
470-505-9905
Email Contact
Good work someconcerns.
Ironically when you try and Google it, the only reference to it now appears here in this forum. Would have been better if they'd never made the mistake, but to err is human I guess.
Can you please give a link to what you're referring to? I went on Fidelity and couldn't find any reference. What often happens is despite the fact that the data provider, Thomson Reuters, corrects it on their end, the sites that have the bad info aren't under any obligation to correct it on their end.
That's why it's totally irresponsible and damaging when someone at a news desk tags the wrong symbol for a particular company. We appear to have paid a little price for just that today. The guy at TR's didn't seem to want to hear about the issue just stating that they made a mistake and fixed it.
It was interesting because the minute I started to point it out, he quickly commented they already knew and had taken steps to amend it.
No doubt they erroneously attributed it to the wrong company. You might check it now, they advised they had already made the proper correction.
It was moved by Roth to 5pm apparently.
Just off the phone with Thomson Reuters who confirmed they were wrong and advised they have now corrected the mistake.
Appears as though someone may have made a mistake somewhere and mistaken the downgrade of Marathon Oil, as Marathon Patent. I'm almost certain Thomson Reuters has never even covered Marathon Patent.
I had never heard of them covering Marathon. Certainly never been mentioned here to my knowledge.
Investors are encouraged to sign up for real time alerts at: http://ir.medovex.com/email-alerts
Ed,
Are you positive on that figure? I believe your figure may exclude 42,564 shares of Common Stock underlying warrants due to a blocker that prevents conversion in excess of 4.99% of the number of outstanding shares of Common Stock. If I'm correct, that cuts your number roughly in half?
They are, but it won't happen overnight and nobody should expect it to. Progress over perfection is just fine at this early stage.
If you spend just a few minutes looking at the management and the boards past track record and accomplishments, it's not difficult to see where they may eventually be going with this.
While they have the DenerveX device that is targeted at a very large market, specifically Facet Joint Syndrome which I believe encompasses about 30% of all lower back pain, they also indicate they intend to make strategic acquisitions.
Makes perfect sense because when you look at the fact they have Dr. Andrews and other world renowned physicians on the board of directors, you could envision them providing an almost unlimited amount of opportunities for the company to consider. Because of who their board members are, they may get a first look at some of the best medtech opportunities in existence.
Bottom line, because of who is involved, there should be no shortage of potential "first look" opportunities being funneled in their deal pipeline. At some point, one could envision some of those opportunities, post being thoroughly vetted, coming out the other end in the form of some potential value creation.
msl,
I don't want to belabor the topic, but will simply say the following. John Stetson was, and still is, a tremendous asset for Marathon. He is wise well beyond his years and what he may have lacked in actual hands on patent experience is far eclipsed by his financial acumen and considerable relationships on the street.
He has repeatedly put his own money where his mouth is, not limited to personally investing approximately $250k in one of the previous financing rounds.
While it's clearly been a team effort, lead by Croxall, Stetson has undoubtedly been an instrumental and foundational team member who has provided immeasurable value in my opinion.
While he may have resigned his physical position on the board to make space for someone with likely more experience and whose more capable of adding more value in light of the company's current positioning, I think it safe to assume he has not resigned even an ounce of his continuing support for the company.
Absolutely concur smallotcinvestor.
Medovex Corporation Signs Manufacturing Agreement for DenerveX Device
ATLANTA, GA--(Marketwired - Feb 12, 2015) - Medovex Corporation. (NASDAQ: MDVX), a developer of medical technology products, announced today that it has signed a manufacturing agreement with Nortech Systems for the DenerveX™ device.
The DenerveX device will be manufactured and assembled in Nortech Systems' Milaca, Minnesota plant. Nortech Systems serves the medical device, aerospace and industrial markets from facilities in the U.S. and Mexico where it provides a full range of manufacturing services for some of the largest medical device companies in the world as well as many early-stage companies in the medical technology space.
Jarrett Gorlin, CEO of Medoxex Corporation stated, "Nortech Systems strong reputation and capabilities in the medical device field makes them an excellent partner for the manufacturing of the DenerveX device. We firmly believe this relationship will ensure that the DenerveX device provides a reliable and effective tool for the treatment of Facet Joint Pain."
"We have been impressed with the Medovex management team and DenerveX device technology," said Rich Wasielewski, President and CEO of Nortech Systems. "We are very excited about partnering in a successful product launch targeting the significant market opportunity for Facet Joint Pain."
About Medovex:
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is designed to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. DenerveX is a trade mark of Medovex Corporation. To learn more about Medovex Corp., visit www.medovex.com
About Nortech:
Nortech Systems Incorporated, based in Wayzata, Minn., is a full-service electronics manufacturing services (EMS) provider of wire and cable assemblies, printed circuit board assemblies, and higher-level complete box build assemblies for a wide range of industries. Markets served include medical, industrial equipment, and aerospace/defense. Our expertise includes Medical Device, Industrial Equipment, Military/Aerospace, Machine Vision, and EMS Contract Manufacturing and Wire & Cable Assembly Solutions Nortech Systems has a wide range of specialized, high-tech facilities used for the customized design, manufacture, testing and repair of its contract manufacturing solutions and cable assembly operations. www.nortechsys.com
Safe Harbor Statement:
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
One step at a time and they should be fine. Foundation is in place, just need to execute going forward.
Regardless of what any specific market maker does, it seems rather indisputable that today's news should fundamentally cause the shares to trade higher and more on par with the intrinsic underlying value of their resource base.
Management is doing all the right things. If they continue to execute, there should be considerable additional upside opportunity here with fairly limited downside risk.
Appreciate your thoughts Ed just as always.
As it pertains to Mr. Stetson, I believe you are referencing both pre-reverse numbers and pre-dividend.
Upon further research, I think you will find my previously posted figures to be currently 100% accurate.
Ed,
Mr. Stetson's position currently stands at the following:
423,000 shares
221,924 Options (not all vested)
11,000 warrants
Not the 2M shares you reference. Furthermore, remember that he remains considered an insider for another 3 months which restricts any sales until at least then.
The news and results really speaks themselves Vegas. Impressive to say the least.
Great commentary smallotcinvestor. Appreciate you sharing it.